We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

92 hedge funds and large institutions have $782M invested in Apellis Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more capital invested

Capital invested by funds: $423M → $782M (+$359M)

25% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 28

14.2% more ownership

Funds ownership: 57.09% → 71.28% (+14%)

0% more call options, than puts

Call options by funds: $1.46M | Put options by funds: $1.46M

3% less funds holding

Funds holding: 95 → 92 (-3)

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
92
Holders Change
-3
Holders Change %
-3.16%
% of All Funds
1.99%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.06%
New
14
Increased
35
Reduced
28
Closed
17
Calls
$1.46M
Puts
$1.46M
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$60.7M
2
O
OrbiMed
New York
+$22.6M
3
Morgan Stanley
Morgan Stanley
New York
+$18.7M
4
Citadel Advisors
Citadel Advisors
Florida
+$14.1M
5
Millennium Management
Millennium Management
New York
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$14.2M
2
VC
Vivo Capital
California
-$7.72M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$6.92M
4
NTC
NF Trinity Capital
Hong Kong
-$4.71M
5
VP
venBio Partners
California
-$4.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$6.51M +$3.5M +222,613 +201%
BBA
27
Baker Bros. Advisors
New York
$6.12M +$1.85M +117,647 +60%
Assenagon Asset Management
28
Assenagon Asset Management
Luxembourg
$6.03M +$4.86M +308,992 New
AG
29
Artal Group
Luxembourg
$5.85M +$4.72M +300,000 New
FI
30
Fosun International
China
$5.62M – – –
Charles Schwab
31
Charles Schwab
California
$4.12M +$298K +18,969 +10%
Goldman Sachs
32
Goldman Sachs
New York
$3.85M +$2.19M +139,510 +240%
Bank of America
33
Bank of America
North Carolina
$3.76M +$2.75M +175,094 +999%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$3.31M +$266K +16,932 +11%
Prudential Financial
35
Prudential Financial
New Jersey
$3.1M -$1.01M -64,320 -29%
AA
36
ALPS Advisors
Colorado
$2.65M +$92.4K +5,875 +5%
Deutsche Bank
37
Deutsche Bank
Germany
$2.48M +$1.6M +101,431 +389%
OM
38
Opaleye Management
Massachusetts
$2.24M -$2.52M -160,000 -58%
EP
39
Eversept Partners
New York
$2.03M -$39.8K -2,531 -2%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$1.76M +$206K +13,092 +17%
Swiss National Bank
41
Swiss National Bank
Switzerland
$1.55M +$252K +16,000 +25%
Barclays
42
Barclays
United Kingdom
$1.54M +$1.22M +77,574 +4,907%
TA
43
Teachers Advisors
New York
$1.53M +$91.6K +5,826 +8%
TCIM
44
TIAA CREF Investment Management
New York
$1.29M -$59.2K -3,767 -5%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$1.08M -$21.2K -1,348 -2%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$993K +$217K +13,800 +37%
MCM
47
Moore Capital Management
New York
$985K +$795K +50,527 New
SI
48
Sofinnova Investments
California
$967K – – –
Ameriprise
49
Ameriprise
Minnesota
$937K +$756K +48,058 New
AllianceBernstein
50
AllianceBernstein
Tennessee
$936K – – –
1
2
3 4 5

APLS Hedge Fund Activity: Q1 2019 in Review

92 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2019, worth a combined $782M — up 85% from $423M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of APLS and 14 opened new positions — a net loss of 3 holders — while 28 trimmed existing stakes and 35 added.

The largest buyer was Wellington Management Group, adding an estimated $60.7M. The largest seller was Cormorant Asset Management, cutting an estimated $14.2M.

  • 92 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2019, down from 95 in Q4 2018.
  • Funds reported $782M of Apellis Pharmaceuticals stock for Q1 2019, up 85% quarter-over-quarter.
  • 14 funds opened new Apellis Pharmaceuticals positions in Q1 2019 and 17 closed out, a net change of -3 holders.
  • The largest Apellis Pharmaceuticals buyer in Q1 2019 was Wellington Management Group, an estimated $60.7M added.
  • The largest Apellis Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $14.2M sold.

Based on aggregated 13F filings for Q1 2019.